Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of 
Non-small Cell Lung Cancer with MET Alterations

Shuzhan LI, Xinwei ZHANG

Abstract


Mesenchymal to epithelial transition factor (MET) gene alterations involve in the proliferation, invasion, and metastasis of non-small cell lung cancer. MET-tyrosine kinase inhibitors (TKIs) have been approved to treat non-small cell lung cancer with MET alterations, and resistance to these TKIs is inevitable. Molecular mechanisms of resistance to MET-TKIs are completely unclear. The review focused on potential mechanisms of MET-TKIs resistance and therapeutics strategies to delay and prevent resistance.


DOI: 10.3779/j.issn.1009-3419.2023.102.33

Keywords


Lung neoplasms; Mesenchymal to epithelial transition factor; Targeted therapy; Drug resistance; Treatment strategy

Full Text: PDF HTML

0 Citation
Alert me when cited by CSCD.
 

Bookmark and Share


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.